Podzamczer, D.Tiraboschi, J.M.Mallolas, J.Curto, J.Cardenes, M.A.Casas, E.Castro-Iglesias, ÁngelesEchevarría, S.Leal, M.López Bernaldo de Quirós, J.C.Moreno, SantiagoPuig, T.Ribera, E.Villalonga, C.Gómez-Sirvent, J.L.García-Henarejos, J.A.López-Aldeguer, J.Barrufet, P.Force, L.Santos, I.Sanz, J.2019-01-252019-01-252012-09Podzamczer D, Tiraboshi JM, Mallolas J, et al. Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years. Curr HIV Res. 2012; 10(6): 513-5201570-162Xhttp://hdl.handle.net/2183/21621[Abstract] OBJECTIVE: To evaluate long-term outcomes in patients maintaining a nevirapine (NVP)-based regimen. METHODS: Retrospective, multicenter, cohort study including patients currently receiving an NVP regimen that had been started at least 5 years previously. Demographic, clinical, and analytical variables were recorded. RESULTS: Median follow-up was 8.9 (5.7-11.3) years. Baseline characteristics: 74% men, 47 years old, 36% drug users, 40% AIDS, 40% HCV+, 51.4% detectable HIV-1 viral load, CD4 count 395 (4-1,421)/μL, 19% CD4 < 200/μL, 27% ALT grade 1-2, 36% AST grade 1-2. Thirty percent ART-naive, 83%received NVP associated with 2 nucleoside analogues during the study period, and 17% a protease inhibitor. A significant improvement was observed in general health status markers, including hemoglobin, platelets, and albumin, regardless of HCV coinfection. CD4 cell gain was +218 and +322/μL after 6 and 9 years, respectively (+321 and +391 in naive patients). Triglycerides significantly decreased in pretreated patients, whereas the percentage of patients with HDLc < 1.03 mmol/L and LDL-c > 3.37 mmol/L significantly decreased in a subsample with available values. A significant decrease in transaminases, alkaline phosphatase, and Fib4 score was observed, mainly in HCV+ and ARV-naive patients. CONCLUSIONS: In patients who tolerate NVP therapy, (even those with HCV coinfection), long term benefits may be significant in terms of a progressive improvement in general health status markers and CD4 response, a favorable lipid profile, and good liver tolerability.engThe published manuscript is avaliable at Eureka SelectNevirapineAntiretroviral therapyLong term benefitsTolerabilityLiver outcomejournal articleopen access